Kornimate/medical-research-clean huggingface dataset:
evaluation of the duration of effect of bimatoprost sr in participants with open-angle glaucoma or ocular hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: this study evaluates the duration of intraocular pressure (iop)-lowering effect and safety of as needed administrations of bimatoprost sustained release (sr) in participants with open-angle glaucoma (oag) or ocular hypertension (oht) who are not adequately managed with topical iop-lowering medication for reasons other than medication efficacy.


Eligibility criteria:
inclusion criteria: - diagnosis of either open angle glaucoma (oag) (i.e., primary oag, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment. exclusion criteria: * concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study. * previous administration with bimatoprost sr in the study eye.

Keywords: open-angle glaucoma (oag) ocular hypertension (oht) bimatoprost
diagnostic value of portable ultrasound for dyspneic patient support in the emergency department

Conditions: Dyspnea

Summary: the main objective of our study is to compare the effects of two care strategies for dyspneic patients on the length of hospital stay: (1) standard care (=contextual analysis + conventional clinical chest radiography) versus (2) standard care + pleuropulmonary ultrasound.

the secondary objectives of this study are to assess the following for both arms: a-fatality rate, b-degree of concordance between the diagnosis orientation in the emergency department and final diagnosis determined by an expert committee using patient records one month later (blind evaluation by a panel of experts) c-clinical improvement between early emergency care and later care outside the emergency department (clinical parameters = blood gases and other biological parameters) d-imaging parameters.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * patient consulting in the emergency department for dyspnea exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient cannot read french * the patient is pregnant, parturient, or breastfeeding

Keywords: vscan portable ultrasound emergency care emergency room
clinical trial of aesculus hippocastanum and associations versus diosmina and hesperidina in chronic venous insuficiency

Conditions: Chronic Venous Insufficiency

Summary: to demonstrate the clinical non-inferiority of efficacy between aesculus hippocastanum, polygonum acre, smilax pepyracea, rutin and diosmin 450mg and hesperidin 50mg tablets in the improvement of lower limb symptoms assessed by means of a 100mm visual scale (vas) over 3 months among adult patients presenting with chronic venous insufficiency of the lower limbs.

phlebotonics represent a heterogeneous group of therapeutic products of natural or synthetic origin that exhibit effects on edema and/or symptoms related to chronic venous diseasethis class of drugs is effective in improving the symptoms of chronic venous insufficiency and in cases of hemorrhoids and for this reason they have become an established component of the therapeutic arsenal for all phases of these diseases phlebotomics are classified into four categories: benzopyrones, saponins, other plant extracts, and synthetic drugs

Eligibility criteria:
inclusion criteria: 1. patient presenting ceap classification from grade c0 to c3 in the evaluation of venous disease of the lower limbs 2. clinical symptoms of chronic venous insufficiency of the lower limbs, defined by the 100mm visual scale performed by the patient between 20mm and 60mm in the most symptomatic lower limb. 3. for female patients of reproductive age, not pregnant or breastfeeding, using reliable contraceptives. 4. patient read, understood, signed and dated the free and informed consent form exclusion criteria: 1. treatment with compression stockings within 2 months of study inclusion date 2. treatment with venotonics within 2 months of the date of inclusion in the study 3. women of reproductive age who are pregnant or breastfeeding, or who do not wish to use contraception during the study period. 4. known allergy or hypersensitivity to any component of the study drug 5. known significant laboratory abnormality 6. ceap grade assessment of level 4, 5, or 6. 7. patient with venous disease requiring intravenous chemical surgery/sclerotherapy 8. patient presenting with a painful pathology in addition to venous pain in the lower limbs 9. patient with a history of thrombosis or thromboembolic disease within 6 months of the date of inclusion in the study 10. patient with a change in general condition that is incompatible with his/her participation in the study 11. patient who wishes to become pregnant within 6 months
acupuncture and acupressure for postoperative nausea and vomiting in children undergoing outpatient middle ear surgery

Conditions: Nausea; Vomiting; PONV

Summary: the specific aim of this study is to determine the incidence of post-operative nausea and vomiting (ponv) in the pediatric population undergoing outpatient middle ear surgery.

the specific aim of this study is to determine the incidence of post-operative nausea and vomiting (ponv) in the pediatric population undergoing outpatient middle ear surgery receiving our institution's standard dual prophylactic antiemetic therapy in combination with intraoperative acupuncture and postoperative acupressure compared to those receiving only the standard dual prophylactic antiemetic therapy.

Eligibility criteria:
inclusion criteria: * healthy asa 1 and 2 patients * age 2 to 18 years old * undergoing outpatient middle ear surgery exclusion criteria: * asa 3 and above * patients with underlying pro-emetogenic disease * patients currently taking antiemetic agents * pregnant women * cognitively impaired adults * prisoners * history of bleeding disorder * age less than 2 or greater than 18

Keywords: acupuncture acupressure
impact of papillary microcarcinoma terminology on patients treatment preferences: a cross sectional survey

Conditions: Thyroid Cancer

Summary: to explore how a clinical sample of patients with thyroid nodules (men and women) with no history of thyroid cancer would make decisions about treatments based on different terminology used to describe papillary thyroid cancer (with and without the cancer term).


Eligibility criteria:
inclusion criteria: * able to complete a survey exclusion criteria: * none
treatment of recurrent aphthous stomatitis with er,cr:ysgg laser irradiation

Conditions: Stomatitis, Aphthous

Summary: the aim this study was to investigate the efficacy of er,cr:ysgg laser irradiation in reducing pain and on healing rate of recurrent aphthous stomatitis 40 patients with ras were included to the study. for each patient, ulceration were randomly assigned to the test or the control group. in test group ras irradiated with er,cr:ysgg laser using non-contact mode. in the placebo group, the same er,cr:ysgg laser without laser emission was used. pain was evaluated with visual analog scale (vas). healing of ras (hras) was graded by a clinician.


Eligibility criteria:
inclusion criteria: * for inclusion every patient had to have one pairs of minor ras duration of 3 days or less, in the buccal or labial nonkeratinized oral mucosa. exclusion criteria: * patients with a known systemic disease that predisposed them to ras (e.g., behçet disease), presence of any major herpetic lesions, traumatic ulcers, ulcers caused due to topical or systemic medications, or undergoing systemic or local treatment for ras were excluded.
oral micronized progesterone effects on perimenopausal menstrual flow

Conditions: Perimenopause; Menstrual Cramps

Summary: this study is designed to evaluate the within-woman effect of oral micronized progesterone (progesterone 300 mg at bedtime) on semi-quantitative menstrual flow measured by the divacup® (menstrual cup with volume indicators at 7.5, 15 and 30 ml) or by counting the number of soaked normal-sized sanitary products such as normal-sized tampons or pads as well as length of flow and frequency and severity of menstrual cramps (on a 0-4 scale) in women with hot flushes and night sweats who are qualified to enroll in the primary perimenopausal hot flush trial stratified by whether they are in early or late perimenopause.

the study will be a double-masked, placebo-controlled 28-day (4 week) baseline, 84-day (12 week) experimental trial, with a maximum number of 125 potential enrollees, with stratified random therapy assignment by early or late perimenopause. participants who meet the inclusion criteria for the original progesterone for perimenopausal vasomotor symptoms study will be invited to join this additional sub-study. as part of the primary trial they will be randomly assigned into either the progesterone or placebo group on a 1:1 basis. primary and secondary data will be collected continuously throughout the study by completion of the daily perimenopause diary-flow starting at baseline and continuously throughout the study.

Eligibility criteria:
inclusion criteria: * \>35 to \<58 years of age * willingness to participate in this sub-study * perimenopausal status either based on irregularity of menstrual periods, or by onset of hot flushes/night sweats in women with regular periods * ability and willingness to complete the -flow recording instrument * ability to understand, speak, read and write english. exclusion criteria: * less than 35 or greater than 58 years of age * more than 1-yr without menstrual flow at study enrollment, including those with a hysterectomy ± ovariectomy * peanut allergy (because peanut oil is used in the progesterone formulation) * current or recent (within 6-mo of study enrollment) use of hormonal therapies (estrogen, progesterone, progestin-releasing intrauterine device (iud), hormonal contraceptives, hormonal fertility treatments), or plans to initiate use during the study period * planned pregnancy or fertility treatment during the study period * inability to understand, speak, read and write english

Keywords: progesterone menstrual flow
mk-0524b lipid study (mk-0524b-063)

Conditions: Primary Hypercholesterolemia; Mixed Dyslipidemia

Summary: this is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of mk-0524b compared to mk-0524a + simvastatin on lipid values.


Eligibility criteria:
inclusion criteria: * has primary hypercholesterolemia or mixed dyslipidemia based on medical history (previous diagnosis), historic lipid values, or as otherwise determined through optional lipid measurements at screening visit * meets one of the following triglyceride (tg) criteria: 1. is on niacin, statin, or fibrate and has tg \<500 mg/dl at or within 6 months of washout 2. is not on any lipid altering therapy or is on lipid altering therapy other than niacin, statin, or fibrate and has tg \<600 mg/dl at or within 6 months of screening exclusion criteria: * is high risk (coronary heart disease \[chd\] or chd risk equivalent) and is on a statin * is pregnant or breast-feeding, or expecting to conceive during the study including the 14-day post study follow-up * has type 1 or type 2 diabetes mellitus and is on statin therapy, is poorly controlled, is newly diagnosed (within 3 months of visit 1), has recently experienced repeated hypoglycemia or unstable glycemic control or is taking new or recently adjusted anti-diabetic medications (with the exception of +/- 10 units of insulin) within 3 months of visit 1 * has the following conditions: chronic heart failure, uncontrolled/unstable cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary disorder or hepatic disease, human immunodeficiency virus (hiv) positive, gout (within 1 year)
addressing colorectal cancer in south florida firefighters

Conditions: Colorectal Cancer; CRC

Summary: the standard way of screening for colorectal cancer is to have a series of fecal blood tests, where a sample is taken from a participant's stool, or an endoscopic procedure performed by a doctor, where a camera is used to look inside the bowel. this research study will use a test performed by the participant. this test will look for changes in the stool that can identify if participants are at higher risk for cancer. another aim of this study is to better understand what firefighters and retired firefighters think about colorectal cancer and other health issues. this information will help us develop programs that may improve colorectal cancer outcomes in the firefighter community.


Eligibility criteria:
inclusion criteria: * for this study, participation is open to active and retired firefighters: 1. ≥ 40 and ≤ 65 years of age, 2. who work or worked in florida fire and rescue departments and 3. report never having fecal occult blood test (fobt) or sigmoidoscopy/colonoscopy in their life or only one fobt in the past year, a sigmoidoscopy in the last 5 years or a colonoscopy in the last 10 years. the research assistant will assess eligibility using a brief screener that will be completed online via redcap. * for years 2 and 3 of the study, the investigators will enroll previously eligible participants who did not complete colorectal cancer (crc) screening during year 1. the investigators will also enroll participants who completed fecal immunochemical test (fit) with our study during year 1 and 2. they will be contacted via redcap and a follow up phone call at the 1 year mark of their previous screening. based on national guidelines, fit screening is suggested on a yearly basis. the eligibility criteria will be the same and participants will sign a revised informed consent form, stating that they understand that they are being re-consented for the same study. * participants, ages 50-65 years old, meeting the above criteria who declined the offered standard-of-care fit will then be offered the blood-based septin9 test 90 days from the initial offering. fda guidelines require the participant to be at least 50 years old to participate in the septin9 blood collection. the blood based test will be collected by a nurse or certified phlebotomist in the community setting. exclusion criteria: * individuals, who have a personal history of crc, inflammatory bowel disease (ie, crohn disease involving the colon or ulcerative colitis) will be excluded from participation as these conditions increase the likelihood of positive test results not associated with the onset or recurrence of crc disease. additionally, individuals will be excluded if they are not physically capable of performing the fit themselves. * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners
ofa - opioid free anesthesia

Conditions: Postoperative Pain

Summary: opioids have been used for analgesia since many years, but despite potent analgesia they are also associated to side effects, including opioid induced hyperalgesia (oih). oih in the surgical setting is debated, and may predispose patients to higher analgesic consumption in the preoperative period, and peripheral and central sensitization. the aim of the study is to compare remifentanil-based vs non opioid analgesia (clonidine, lidocaine, ketamine) for intraoperative management of patients undergoing laparoscopic left hemicolectomy, with the hypothesis that non- opiod treated patients will have lower morphine consumption in the first 24 hours after surgery. peripheral and central hyperalgesia will be tested with von frey hairs and pin-prick to evaluate acute cns (central nervous system) sensitization after surgery. acute and persistent (1 and 3 months) pain will be registered, together with any side effect and parameters of surgical rehabilitation.


Eligibility criteria:
inclusion criteria: * left hemicolectomy * signed informed consent * \>18 ys exclusion criteria: * \>90 ys \<18 ys * no consent * pregnancy * psychiatric disease * cardiac failure, aortic or mitral valve severe stenosis * kidney or hepatic failure * atrio-ventricular type ii block * immunodepression * emergency surgery * icu admittance * drug or alcohol abuse * chronic pain
safety and efficacy clinical study of sns-595 for second-line therapy in patients with advanced nsclc

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to evaluate the objective tumor response rate (based on the recist criteria) to sns-595 as a second-line therapy in patients with advanced nsclc.

other objectives of this study are to assess the safety, tumor response, time to disease progression, survival rate and to explore several potential biomarkers to see how these levels change after administration of sns-595.

Eligibility criteria:
inclusion criteria: * able to understand and willing to sign a written informed consent document * patients who have recurrent or metastatic nsclc, who have failed initial therapy with a platinum-containing regimen and have not received any second-line therapy (adjuvant therapy is acceptable if it was completed greater than or equal to 12 months before the cancer recurrence) * measurable disease * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * laboratory values within the normal or reasonable reference range as specified by the protocol exclusion criteria: * prior exposure to sns-595 * pregnant or breastfeeding * women of childbearing potential or male partners of women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards * other active malignancies or other malignancies within the past 12 months except non-melanoma skin cancer, cervical intraepithelial neoplasia or prostatic intraepithelial neoplasia * brain metastases, if present, without radiologic evidence of progressive disease for at least 3 months after completion of therapy * myocardial infarction, cerebrovascular accident/transient ischemic attack (tia) or thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months before the first sns-595 dose * requires kidney dialysis (hemodialysis or peritoneal) * prior chemotherapy, investigational agents, or radiation therapy within 28 days before cycle 1 day 0; however, nitrosoureas and mitomycin are not permitted for at least 42 days before cycle 1 day 0 * in patients with toxicities caused by prior cancer therapy, those toxicities must have returned to less than or equal to grade 1, with the exception of alopecia * prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone marrow reserve (prior palliative radiation is permitted as long as it does not exceed 25% of bone marrow reserve) * any other medical, psychological, or social condition that, in the opinion of the principal investigator, would contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with study procedures

Keywords: lung squamous cell large cell adenocarcinoma carcinoma cancer
stress management for couples undergoing in vitro fertilization (ivf)

Conditions: Infertility

Summary: the investigators are trying to determine stress management strategies in couples undergoing in vitro fertilization (ivf).

the investigators are trying to determine two different stress management techniques in couples undergoing ivf. one arm will be randomized to learning these techniques by themselves by watching and following instructions on a digital video disc (dvd). the other arm will have an in-person class that will teach the couples different stress reduction techniques.

Eligibility criteria:
inclusion criteria: * women with clinical infertility, either primary or secondary, who are recommended for ivf for the first time as part of their treatment for infertility * women with a partner, and both are willing to provide consent for study participation as a couple * couples that can be reached by telephone for follow-up exclusion criteria: * women less than 18 years of age * women equal or greater than 40 years of age * women with a history of recurrent pregnancy loss * history of current or recent psychotic episode within past 6 months for either the woman or her partner * couples needing a interpreter for their clinical encounter

Keywords: infertility in vitro fertilization (ivf) stress management stress reduction
posterior capsule opafication of different hydrophobic acrylic intraocular lenses: vivinex isert p261 vs.clareon iol

Conditions: Age Related Cataracts

Summary: on the day of surgery, the first eye to be operated is randomised to receive a vivinex , hoya surgical optics gmbh or an clareon, alcon, fort worth, texas. the second eye to be operated receives the other iol type. a complete biomicroscopic examination, visual acuity testing using autorefractometer, contrast sensitivity testing, and standardised retroillumination photography for pco evaluation, will be performed 6 month (30-60 days), 1.5 years (± 3 months) and 3 (± 3 months) years postoperatively.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract for which phacoemulsification extraction and posterior iol implantation has planned * age 50 and older * visual potential in both eyes of 20/30 or better as determined by investigators estimation * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant exclusion criteria: * preceding intraocular surgery or ocular trauma * relevant other ophthalmic diseases (such as pseudoexfoliation, glaucoma, uveitis, retinal degenerations, etc.) * laser treatment * uncontrolled systemic or ocular disease * infectious disease * pregnancy/nursing